Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Payables (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Payables for 9 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • Quarterly Payables fell 70.1% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2025, down 70.1% year-over-year, with the annual reading at $3.3 million for FY2025, 70.1% down from the prior year.
  • Payables for Q4 2025 was $3.3 million at Denali Therapeutics, down from $6.7 million in the prior quarter.
  • The five-year high for Payables was $13.9 million in Q2 2024, with the low at $1.2 million in Q3 2023.
  • Average Payables over 5 years is $6.6 million, with a median of $6.9 million recorded in 2023.
  • The sharpest move saw Payables crashed 84.32% in 2023, then skyrocketed 711.68% in 2024.
  • Over 5 years, Payables stood at $4.8 million in 2021, then crashed by 41.62% to $2.8 million in 2022, then soared by 239.89% to $9.5 million in 2023, then rose by 17.44% to $11.1 million in 2024, then plummeted by 70.1% to $3.3 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $3.3 million, $6.7 million, and $10.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.